Management Team

JC Gutiérrez-Ramos
President and Chief Executive Officer
Dr. JC Gutiérrez-Ramos joined Synlogic in April 2015 from Pfizer, where he served as group senior vice president and global head of biotherapeutics research. In that role, he held responsibility for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in rare disease discovery and development and founded the Centers for Therapeutic Innovation. He oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. JC previously held the position of senior vice president and head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc) into therapeutics. Prior to his work in the pharmaceutical industry, JC held senior leadership positions at several biotech companies; He was senior vice president and head of R&D at Avidia Inc. and Peptimmune Inc., where he led a significant efforts focused on the discovery of novel protein therapeutics and peptides for autoimmune disease, including multiple sclerosis and diabetes. He began his career in the drug industry at Millennium Pharmaceuticals serving as vice president of inflammation drug discovery. In that capacity he was responsible for advancing preclinical candidates in inflammation and immunology into human clinical trials and advancing compounds (small molecules and antibodies) from discovery through clinical development. JC began his career in academia as part of the faculty at the genetics department of Harvard Medical School. He was member of the Basel Institute for Immunology in Basel, Switzerland and a fellow at the Max-Plank Institute in Freiburg, Germany. He has co-authored more than 150 peer-reviewed publications. JC holds a Ph.D. in immunochemistry from the Autonoma University in Madrid, Spain.
Todd Shegog
Chief Financial Officer
Todd Shegog joined Synlogic in September 2016 as chief financial officer and is responsible for the oversight and direction of the company’s financial strategy and management as well as facilities and information systems. Todd brings more than 20 years of financial experience in the biotechnology and pharmaceutical industries. Most recently, Todd served as senior vice president and chief financial officer at Forum Pharmaceuticals, where he was responsible for finance, operations and information systems in support of the pursuit of innovative therapies for schizophrenia and Alzheimer’s disease. Prior to Forum, Todd was the senior vice president and chief financial officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company’s financial resources, corporate planning, financial reporting and compliance. During his tenure from 1998 to 2014, Todd held key leadership roles supporting the early evolution of the company and its transformation from a genomics company to a fully-integrated drug developer, the approval and launch of its flagship oncology product, VELCADE®, and the $8.8 billion acquisition of Millennium by Takeda Pharmaceuticals. He began his career in healthcare at Genetics Institute (now Pfizer) in a variety of financial positions supporting its research and development organizations and was a member of the commercial operations team that supported the launch of BeneFIX®. Todd holds an MBA from the Tepper School of Management at Carnegie Mellon University and a bachelor’s degree in electrical engineering from Lafayette College.
Aoife M. Brennan
Chief Medical Officer
Dr. Aoife Brennan joined Synlogic in September 2016 as chief medical officer and is responsible for the oversight and direction of the company’s clinical development strategy and operations. Aoife previously spent six years at Biogen, where she was in roles of increasing responsibility and most recently served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX™ and ELOCTATE™, treatments for Hemophilia B and Hemophilia A. Prior to joining Biogen, she was director of clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Paul Miller
Chief Scientific Officer
Dr. Paul Miller joined Synlogic in 2014 as chief scientific officer and is accountable for all aspects of discovery research and platform expansion at the company. Previously, Paul was the vice president of infection biology at AstraZeneca, where he was responsible for the early discovery portfolio and strategy while also leading several external collaborations. Prior to Astra-Zeneca, Paul was the chief scientific officer for antibacterial research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several successful marketed antibiotics including Zithromax and Zyvox, and also successfully advanced a novel oxazolidinone (sutezolid) for tuberculosis into Phase II studies. A microbial geneticist by training, Paul began his professional career at the Warner-Lambert Company in Ann Arbor, Michigan, where he integrated modern molecular-genetic approaches into a traditional antibacterial drug discovery program and established novel target discovery projects. His work there led to new insights into the mechanisms by which bacteria sense and respond to antibiotics and other environmental agents. Paul received his Ph.D. in microbiology and immunology from the Albany Medical College, and conducted post-doctoral studies at the National Institutes of Health. He has also served as a member of the Institute of Medicine’s Forum on Microbial Threats.
Richard M. Schwartz
Senior Vice President, Process Development and Manufacturing
Dr. Richard Schwartz joined Synlogic in September 2016 as senior vice president of process development and manufacturing, where he is responsible for the oversight and management of process development and manufacturing of Synlogic’s product candidates. Previously, Richard was the chief of the Vaccine Production Program (VPP) at the Vaccine Research Center (VRC) at the NIAID/NIH. At the VRC, he was responsible for development and clinical production of vaccines against viruses which include HIV, Ebola, Zika, Influenza, Chikungunya and Equine Encephalitis, as well as the first broadly neutralizing monoclonal antibody against HIV. Richard has 30 years of experience in pharma and biotech working in diverse areas including pharmaceutical natural product production, hematopoietic stem cells, vaccines and therapeutic proteins. Richard was previously the senior director of process and manufacturing sciences at MedImmune Vaccines (formerly Aviron), where he was responsible for vaccine development and clinical manufacturing of new vaccine candidates, as well as for providing support to commercial vaccine manufacturing operations. Additionally, he was team lead for a BARDA-funded development effort to convert FluMist from an egg-based to a cell culture--based production process. Prior to MedImmune, Richard worked at SyStemix, Aastrom Biosciences and Eli Lilly. Richard received his bachelor’s degree, master’s degree and Ph.D. in chemical engineering from the University of Michigan.
Caroline B. Kurtz
Head of Translational Sciences and Product Development
Dr. Caroline Kurtz joined Synlogic in October 2016 and is responsible for all aspects of nonclinical development for Synlogic’s therapeutic programs. Previously, Caroline was vice president and GC-C platform lead at Ironwood Pharmaceuticals, where she drove the development of linaclotide (LINZESS®) from pre-IND through NDA approval and life-cycle management. In this role, she managed the linaclotide development collaborations with U.S. partner Forest (now Allergan), European partner Almirall and Japanese partner Astellas. Through the study of linaclotide’s pharmacology, her team identified a novel mechanism for the relief of visceral pain mediated by the release of cGMP from intestinal epithelial cells. She also served as the portfolio lead for the discovery and development of new GC-C agonists, including identification of two additional clinical candidates. Prior to her role at Ironwood, Caroline served as director of infectious diseases at GelTex/Genzyme, where she led discovery of novel polymeric compounds as anti-infectives for intestinal and pulmonary infections. This work led to the discovery and clinical development of a toxin-binding polymer, tolevamer, for the treatment of C. difficile colitis. Caroline received her Ph.D. in immunology from Harvard University in the laboratory of Dr. John Weis, and post-doctoral training in viral immunology and central nervous system demylelinating diseases in the laboratory of Dr. Robert Fujinami at the University of Utah. She was recently recognized by PharmaVoice magazine as one of 2016’s 100 most inspiring people.
Dean Falb
Chief Technology Officer
Dr. Dean Falb joined Synlogic in November 2013 as co-founder and chief technology officer where he is responsible for platform technology development and therapeutic program initiation. Previously, Dean was an entrepreneur in residence at Atlas Ventures and worked on several of its emerging portfolio companies. Prior to this, he was vice president of research and development at Stryker’s regenerative medicine division. There, he led the discovery and development of a portfolio of Bone Morphogenetic Protein (BMP)-based drugs and drug device combinations and launched clinical programs in osteoarthritis. Dean was senior vice president of R&D at Praecis Pharmaceuticals, where he led the discovery and development of peptide-based drugs in several therapeutic indications including Plenaxis, which was approved by the FDA for patients with prostate cancer. In 1993, Dean was hired as a founding scientist at Millennium Pharmaceuticals, where he started and led Millennium’s program in cardiovascular diseases. There, he discovered the SMAD signal transduction family, which functions downstream of BMP/TGF-beta receptors. He also led a large collaboration with Eli Lilly around the genetics and genomics of cardiovascular diseases. Before Millennium, Dean was a scientist at Immulogic Pharmaceuticals. Dean received his Ph.D. in biochemistry and molecular biology in the lab of Tom Maniatis at Harvard University.
Andrew Gengos
Chief Operating Officer and Head of Corporate Development
Andrew Gengos joined Synlogic in October 2017 as Chief Operating Officer and Head of Corporate Development and is responsible for leading and coordinating strategic corporate and business development for the company. Andrew brings over 25 years of senior leadership experience in the biotechnology and pharmaceutical industries, holding key positions at companies focused on advancing innovative products and technologies. He most recently served as President, Chief Executive Officer and as a director of ImmunoCellular Therapeutics, an immune-oncology company pursuing treatments for glioblastoma. Previously, Andrew was the President and Chief Executive Officer of Neuraltus Pharmaceuticals. He served for more than seven years as Vice President, Strategy and Corporate Development at Amgen, where he managed all business development activities, led the execution of strategic projects and supported the company’s long-range planning. Prior to that, he served as Vice President, Chief Financial Officer and Chief Business Officer of Dynavax Technologies where he was responsible for all business and finance activities. Earlier in his career, Andrew served as Vice President of Strategy at Chiron Corporation (now Novartis) and as a Senior Engagement Manager at McKinsey & Company. Andrew holds an MBA degree from the UCLA Anderson School of Management and a BS degree in chemical engineering from the Massachusetts Institute of Technology.
Adam Thomas
Chief Human Resources Officer
Adam Thomas joined Synlogic in July 2017 and is responsible for all human resource functions including staffing and recruitment, leadership development and learning, and compensation and talent engagement approaches. Adam has spent more than 20 years in human resources helping leading companies recruit and retain top talent. Prior to joining Synlogic, he served as Vice President and Head of Human Resources for Research and Development at Shire during a period when the company underwent major expansion, doubling the size of its research and development workforce in Massachusetts. Before joining Shire, Adam served as Head of Human Resources for Research, Development, and Engineering for S.C. Johnson and Company. Earlier in his career he served as director in various human resources functions at Pfizer. Adam holds an M.B.A. from Boston University, a Bachelor of Laws degree (LL.B.) from the University of Edinburgh and an M.A. from the University of the West of England.